- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- CAM2029, Octreotide LAR, Lanreotide ATG
- Drug
- Lead sponsor
- Camurus AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumors With PTCH1 Loss-of-function Mutations
- Interventions
- ENV-101 (taladegib)
- Drug
- Lead sponsor
- Endeavor Biomedicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor
- Interventions
- Quarfloxin
- Drug
- Lead sponsor
- Cylene Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Denver, Colorado • Fort Collins, Colorado + 10 more
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Interventions
- 18F-mFBG
- Drug
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Interventions
- PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
- Interventions
- 68Gallium DOTATATE, Radio-guided surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 10 Years to 99 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
- Interventions
- MK-0646
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
- Interventions
- Surufatinib
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Orange, California • Atlanta, Georgia + 2 more
- Conditions
- Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
- Interventions
- 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tumor Hyperinsulinism (Tumor HI)
- Interventions
- Ersodetug
- Drug
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gastro-Enteropancreatic Neuroendocrine Tumor
- Interventions
- Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuroendocrine Tumor
- Interventions
- 90Y-DOTA-TOC, 68Ga-DOTA-TOC
- Drug
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Neuroendocrine Tumors of Pancreatic Origin
- Interventions
- Everolimus, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Interventions
- Lutetium [177Lu] oxodotreotide/dotatate
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2034
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Neuroendocrine Carcinoma, Neuroendocrine Tumors
- Interventions
- Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
- Interventions
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Radiation · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
- Conditions
- Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
- Interventions
- Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
- Drug · Other
- Lead sponsor
- Chandrikha Chandrasekhara
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
- Interventions
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Drug
- Lead sponsor
- Perspective Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 19
- States / cities
- Jacksonville, Florida • Miami, Florida • Chicago, Illinois + 16 more
- Conditions
- Non Functioning Entero-pancreatic Endocrine Tumour
- Interventions
- lanreotide (Autogel formulation)
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Baltimore, Maryland
- Conditions
- Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
- Interventions
- Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
- Drug · Combination Product
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 4
- States / cities
- La Jolla, California • Miami, Florida • Buffalo, New York + 1 more
- Conditions
- Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
- Interventions
- [203Pb]VMT-α-NET, SPECT/CT
- Drug · Device
- Lead sponsor
- Yusuf Menda
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
- Interventions
- Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland